title: A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Neha
authors.initials: N
authors.lastname: Korde
authors.affiliation: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Mattias
authors.initials: M
authors.lastname: Carlsten
authors.affiliation: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Min-Jung
authors.initials: MJ
authors.lastname: Lee
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Alex
authors.initials: A
authors.lastname: Minter
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Esther
authors.initials: E
authors.lastname: Tan
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Mary
authors.initials: M
authors.lastname: Kwok
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Elisabet
authors.initials: E
authors.lastname: Manasanch
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Manisha
authors.initials: M
authors.lastname: Bhutani
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Nishant
authors.initials: N
authors.lastname: Tageja
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Roschewski
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Adriana
authors.initials: A
authors.lastname: Zingone
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Rene
authors.initials: R
authors.lastname: Costello
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Marcia
authors.initials: M
authors.lastname: Mulquin
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Diamond
authors.initials: D
authors.lastname: Zuchlinski
authors.affiliation: Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Irina
authors.initials: I
authors.lastname: Maric
authors.affiliation: Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Katherine R
authors.initials: KR
authors.lastname: Calvo
authors.affiliation: Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Raul
authors.initials: R
authors.lastname: Braylan
authors.affiliation: Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Prashant
authors.initials: P
authors.lastname: Tembhare
authors.affiliation: Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Constance
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Maryalice
authors.initials: M
authors.lastname: Stetler-Stevenson
authors.affiliation: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Jane
authors.initials: J
authors.lastname: Trepel
authors.affiliation: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Childs
authors.affiliation: Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA landgrec@mskcc.org.
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy*; D054340:Receptors, KIR / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D054340:Receptors, KIR; C558235:IPH-2101
keywords: HLA-C binding KIR2D reports; IPH2101; KIR2D blockade; NK-cell function; clinical response; smoldering multiple myeloma